| Literature DB >> 26617211 |
Sabrina Witherby1, Tina Rizack2, Bachir J Sakr2, Robert D Legare2, William M Sikov3.
Abstract
Standard management of early stage and advanced breast cancer has been improved over the past few years by knowledge gained about the biology of the disease, results from a number of eagerly anticipated clinical trials and the development of novel agents that offer our patients options for improved outcomes or reduced toxicity or both. This review highlights recent major developments affecting the systemic therapy of breast cancer, broken down by clinically relevant patient subgroups and disease stage, and briefly discusses some of the ongoing controversies in the treatment of breast cancer and promising therapies on the horizon.Entities:
Mesh:
Substances:
Year: 2015 PMID: 26617211 DOI: 10.1016/j.semradonc.2015.09.005
Source DB: PubMed Journal: Semin Radiat Oncol ISSN: 1053-4296 Impact factor: 5.934